TICKERNERD
Menu
INDPINDPHealthcare · Biotechnology

INDP Stock Forecast: Indaptus Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.16
−10.08% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$171.9M
Ticker Nerd rank
24 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$2.2M
Net income−$2.5M
Free cash flow−$7.0M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+16.0%
1M
−55.6%
YTD
−60.1%
1Y
−84.2%
From 52W high
−83.6%
From 52W low
+23.9%
$0.94
$7.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INDP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Indaptus Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
72
Size
70
Value
58
Issuance
53
Momentum
30
Revisions
25
Volatility
19
Accruals
17
Quality
15

Growth (72): Sales and profits are climbing, and climbing faster than before.

Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INDP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INDP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Oct 25Jan 26Apr 26Jul 26INDP

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2024Maxim GroupMaintainsBuy$8.00 → $5.00
16 Oct 2024HC Wainwright & Co.ReiteratesBuy—
17 June 2024HC Wainwright & Co.ReiteratesBuy—
15 Apr 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
8 Aug 2023HC Wainwright & Co.ReiteratesBuy—
4 May 2023HC Wainwright & Co.ReiteratesBuy—
20 Mar 2023HC Wainwright & Co.MaintainsBuy—
8 Mar 2023HC Wainwright & Co.ReiteratesOverweight—
8 Feb 2023HC Wainwright & Co.ReiteratesBuy—
31 Jan 2022HC Wainwright & Co.AssumesBuy$15
19 Oct 2021Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INDP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INDP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Indaptus Therapeutics, Inc. returned −84.2% against +19.6% for the S&P 500, dividends included.

INDP vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26INDPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INDP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Indaptus Therapeutics, Inc. (INDP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
13.5×

Cheaper than 7% of US stocks

EV / EBITDA
−8.1×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−318.0%

Higher than 5% of US stocks

Return on assets
−98.1%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Indaptus Therapeutics, Inc. (INDP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Indaptus Therapeutics, Inc. has a market value of $171.9M and an enterprise value of $160.3M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$18.9M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$16.8M.

  • Shares outstanding: 113.2M.

  • Trailing P/E: −0.1×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Indaptus Therapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

INDP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INDPIndaptus Therapeutics, Inc.$171.9M
24
HUMAHumacyte, Inc.$173.2M
18
CUECue Biopharma, Inc.$174.2M
47
MDWDMediWound Ltd.$169.4M
29
CNTNCanton Strategic Holdings, Inc.$168.9M
12
CRBUCaribou Biosciences, Inc.$178.0M
57
CDXSCodexis, Inc.$179.6M
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Indaptus Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INDP news & analysis

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 13 Aug 2026neutral

Indaptus Therapeutics reported its financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update. The announcement was made on August 13, 2026, by the immunotherapy-focused biotechnology company.

Why it matters — The quarterly financial report and corporate update offer INDP watchers the company's latest operational and financial position.

FAQ

Frequently asked questions about INDP stock

Is INDP stock a buy right now?

Of the 1 analysts covering Indaptus Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Indaptus Therapeutics, Inc. 24 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INDP?

As at 22 Aug 2026, Indaptus Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (72 of 100).

What is the INDP stock forecast for 2030?

No analyst covering Indaptus Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INDP are extrapolating price history, which says nothing about the business.

How has INDP stock performed over the past year?

Indaptus Therapeutics, Inc. returned -84.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Indaptus Therapeutics, Inc. do?

Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing systemically administered immunotherapies for cancer and chronic viral infections.

What is the latest news on INDP?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update". Indaptus Therapeutics reported its financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update. The announcement was made on August 13, 2026, by the immunotherapy-focused biotechnology company.

Company

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing systemically administered immunotherapies for cancer and chronic viral infections. The company’s core platform leverages proprietary, attenuated, killed, non-pathogenic Gram-negative bacteria engineered to reduce intravenous toxicity while preserving the ability to activate both innate and adaptive immune responses. This approach is designed to deliver a multi-targeted package of immune-stimulating signals that can be given safely via intravenous infusion, aiming to trigger broad anti-tumor and anti-viral activity. Indaptus Therapeutics’ lead candidate, Decoy20, is being developed for solid tumors such as colorectal, hepatocellular, and pancreatic cancers, as well as non-Hodgkin’s lymphoma, and is also being explored in settings related to chronic viral infections including hepatitis B and HIV. Operating within the healthcare and biotechnology sector, and headquartered in New York, New York, the company occupies a niche in the immuno-oncology and immuno-virology landscape, targeting indications where durable immune-driven responses are a key clinical objective.

CEO Mr. Junyi Dai · 5 employees · United States · https://indaptusrx.com